Phenylethylidenehydrazine

Phenylethylidenehydrazine (PEH), also known as 2-phenylethylhydrazone or β-phenylethylidenehydrazine, is a GABA transaminase inhibitor.[1][2] It is a metabolite of the antidepressant phenelzine and is responsible for its elevation of GABA concentrations.[1] PEH may contribute to phenelzine's anxiolytic effects.[3]

Phenylethylidenehydrazine
Clinical data
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Pharmacokinetic data
Elimination half-life~12 hours
Identifiers
  • (1E)-(2-Phenylethylidene)hydrazine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC8H10N2
Molar mass134.182 g·mol−1
3D model (JSmol)
  • N/N=C/CC1=CC=CC=C1

See also

edit

References

edit
  1. ^ a b Parent MB, Master S, Kashlub S, Baker GB (January 2002). "Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular gamma-aminobutyric acid levels in the striatum". Biochemical Pharmacology. 63 (1): 57–64. doi:10.1016/S0006-2952(01)00856-5. PMID 11754874.
  2. ^ Duffy S, Nguyen PV, Baker GB (2004). "Phenylethylidenehydrazine, a novel GABA-transaminase inhibitor, reduces epileptiform activity in rat hippocampal slices". Neuroscience. 126 (2): 423–432. doi:10.1016/j.neuroscience.2004.03.007. PMID 15207360. S2CID 30625470.
  3. ^ Baker GB, Wong JT, Yeung JM, Coutts RT (March 1991). "Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA)". Journal of Affective Disorders. 21 (3): 207–211. doi:10.1016/0165-0327(91)90041-p. ISSN 0165-0327. PMID 1648582.